Oncoshot
Oncoshot is a Singapore-headquartered healthtech company operating a federated AI platform that connects cancer patients, hospitals, and pharmaceutical/CRO sponsors to accelerate oncology clinical trial matching and enrollment, with operations across 7 countries and a network of 20+ hospitals.
- Company typePrivate
- Founded2018
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Oncoshot does
Oncoshot is a Singapore-headquartered healthtech company founded in November 2018 by medical oncologist Dr. Huren Sivaraj (CEO) and data scientist Ruslan Enikeev (CTO) to address oncology clinical trial enrollment inefficiency. The company operates a federated AI-powered real-time health insights exchange platform that connects cancer patients, hospitals, and pharmaceutical/CRO partners. Its core architecture deploys identical federated units inside hospital AWS environments (Amazon EKS, Amazon RDS PostgreSQL), with an in-premise medical LLM that processes unstructured clinical data — free-text notes, pathology reports, CT reports, and genomics — without patient data ever leaving the hospital. A central cluster serves pharma/CRO sponsor users who receive aggregated, de-identified patient population insights and feasibility assessments.
The product surface includes the core Oncoshot Platform, the Recommend Tx LLM-driven patient self-matching tool, the Well-Characterised Registry (WCR) for automated cancer registry data abstraction, and hospital-side modules (Insite Feasibility, Real-Time Insights, Insite Workflow). Project EISE extends the platform as Singapore's nationwide oncology ecosystem. The company serves three primary customer segments: hospitals and cancer centers (B2B subscription access to feasibility, insights, and workflow tools), pharmaceutical/biotech/CROs (subscription access to matching insights and aggregated patient population data), and cancer patients/caregivers (free self-service matching via Recommend Tx, with optional paid assisted support at a one-time $99.90 fee).
Oncoshot monetizes primarily through enterprise subscriptions from hospitals and pharma/CRO sponsors on quote-based annual contracts, supplemented by a freemium patient channel. The platform holds ISO 27001/27017/27018, SOC 2 Type II, HIPAA, GDPR, PDPA, and AWS Qualified Software certifications, plus Singapore HSA clearance and MOH recognition. Operations span Singapore, India, Australia, Taiwan, Japan, China, and the US via MSK iHub collaboration, with a hospital network of 20+ across 7 countries and 100,000+ cancer patients in its ecosystem. The company is privately held (Oncoshot Pte Ltd), has raised approximately $2.36M across pre-seed and pre-Series A rounds led by MassMutual Ventures, and employs 25-30 staff across four regional offices.
Oncoshot firmographics
Firmographics- Name
- Oncoshot
- Legal name
- Oncoshot Pte Ltd
- Website
- https://oncoshot.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Oncoshot is a Singapore-headquartered healthtech company operating a federated AI platform that connects cancer patients, hospitals, and pharmaceutical/CRO sponsors to accelerate oncology clinical trial matching and enrollment, with operations across 7 countries and a network of 20+ hospitals.
- Ownership category
- akta.pro rank
Oncoshot industry classification
Industry- Product category
- Oncology Clinical Trial Matching Software
- NAICS
- Computer Systems Design and Related Services (54151), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (51821)
- SIC
- Services-Health Services (8000), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)
- akta.pro secondary industries
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Clinical Decision Support & Workflow Integration (EHR/oncology systems) (HLAAANAE), Post-Acute & Hospital-at-Home Remote Care Platforms (HLACAFAB)
Keywords
Where Oncoshot is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices4 records
Markets served
Oncoshot business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Platform Access for Industry Partners: Pharma companies and CROs pay for access to the platform to generate matching insights, conduct feasibility assessments, and identify eligible patient populations across the hospital network. Industry partners pay for de-identified patient matching scores and clinical data to facilitate rapid online screening and early trial enrollment.
- Platform Services for Hospitals: Hospitals pay for access to Oncoshot's tools including Insite Feasibility, Real-Time Insights, and Insite Workflow to increase inbound trial opportunities, improve clinical trial processes, and engage with global pharma and biotech partners.
- Patient Support Services: Patients and caregivers access high-value clinical trial recommendations for free. Oncoshot charges a one-time fee of USD 99.90 for individuals who require assistance reviewing full medical records and completing the questionnaire with oncologist support. Oncoshot is never paid a bounty for enrolling a patient into a trial.
- Data-Driven Insights and Analytics: Oncoshot's platform generates aggregated patient population insights from federated hospital data. Pharma and CRO sponsor users apply these insights in decision-making such as determining which countries or trial sites best fit their clinical trial requirements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Free Patient Self-Service Tier |
| One time/ perpetual license | Pay-as-you-go | Assisted Patient Support |
| Subscription | Annual | Hospital and Industry Partner Enterprise Plans |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels9 records
Oncoshot product offering
Product offeringCore offering
Oncoshot operates a federated AI-powered real-time health insights exchange platform that connects cancer patients, hospitals, and pharmaceutical/CRO companies to accelerate oncology clinical trial enrollment. The platform deploys in-premise medical LLMs within hospital AWS environments, enabling AI-driven patient-to-trial matching, automated extraction of structured data from unstructured clinical reports, real-time feasibility assessments, and trial workflow collaboration without patient data ever leaving hospital premises. Hospitals and industry partners subscribe to the platform for trial matching insights, feasibility management, and workflow automation, while patients use a free self-service matching tool.
Product overview
Oncoshot is a federated AI-powered oncology platform structured as a core platform with multiple integrated modules. The core Oncoshot Platform serves as a real-time health insights exchange connecting cancer patients, hospitals, and the healthcare industry via a federated architecture that keeps patient data within hospital environments. The Recommend Tx LLM feature enables patients to self-match to clinical trials via free-text input. The Well-Characterised Registry (WCR) automates cancer registry data abstraction. Hospital-facing modules — Insite Feasibility, Real-Time Insights, and Insite Workflow — manage trial feasibility, patient population monitoring, and workflow automation. Project EISE extends the platform as a national-level Singapore ecosystem. The Feasibility Marketplace connects trial sites with sponsors. The platform is complemented by AWS cloud infrastructure and an in-premise medical LLM.
Differentiator
Problem solved
Functional benefit
Brands
- Project EISE (Enhanced Clinical Trial Initiation, Screening and Enrolment): Singapore's first nationwide collaboration connecting cancer patients, healthcare professionals, and pharmaceutical/biotechnology companies in one ecosystem. Led by Oncoshot leveraging its patient-to-provider matching AI platform.
- Well-Characterised Registry (WCR)
- Recommend Tx
Products and services
- Oncoshot Platform A federated AI-powered real-time health insights exchange platform that connects cancer patients, hospitals, and pharmaceutical/CRO companies to accelerate oncology clinical trial enrollment. Patient data remains within hospital environments while aggregated insights are exchanged through federated LLM units deployed within hospital AWS environments with a central cluster serving pharma/CRO sponsor users.
- Recommend Tx A free-to-use Large Language Model (LLM) AI feature that interprets free-text cancer information submitted by patients to match them with high-value clinical trials. Patients type one or two sentences about their cancer details (diagnosis, stage, medications, biomarkers, mutations); the LLM structures the information and a matching algorithm identifies and ranks relevant trials based on eligibility criteria-based matching scores. Supports multiple languages and is accessible via oncoshot.com/for-patients.
- Well-Characterised Registry (WCR) A federated AI platform for automating cancer registry data abstraction from unstructured pathology reports, CT scans, and clinical documents. Extracts and structures key registry variables including histology, diagnosis, tumour size, and TNM stage with demonstrated over 95% validated accuracy and 97.6% histology extraction accuracy across 1,200+ real-world pathology reports. Operates within secure, isolated hospital environments with no patient data leaving the institution.
- Project EISE (Enhanced Clinical Trial Initiation, Screening and Enrolment) Project EISE is Singapore's first nationwide AI-powered oncology ecosystem led by Oncoshot. It connects cancer patients, public and private healthcare professionals, and pharmaceutical companies in one platform to accelerate trial identification, screening, and enrollment across Singapore.
Quantifiable outcome
- Reduces patient recruitment time from weeks to minutes
- +5 more outcomes
Companies that use Oncoshot
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
Oncoshot technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature8 records
Oncoshot partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered flagship, core and minor.
- Memorial Sloan Kettering Cancer Center (MSK) Innovation HubflagshipCollaboration agreement to explore and potentially extend MSK's Core Clinical Data Elements (CCDE) data model across Oncoshot's APAC hospital network. Creates shared clinical research capabilities between MSK and leading cancer centers in Singapore, India, Japan, and Australia. Enables data harmonization without compromising local governance or patient privacy through Oncoshot's federated LLM-based data extraction systems.
- Curie OncologycorePartnership to deploy AI-powered clinical research tools in Singapore and Malaysia. Oncoshot's AI system processes unstructured clinical data enabling faster identification of eligible patients for trials. The system extracts and de-identifies data with over 95% accuracy. Curie Oncology is one of Southeast Asia's fastest-growing private oncology networks operating across Singapore, Malaysia, and the Philippines.
- Tan Tock Seng HospitalcorePublic sector deployment of Oncoshot's AI platform alongside National Cancer Centre Singapore. Results highlighted in presentations at International Association of Cancer Registries (IACR) 2025.
- National Cancer Centre SingaporecorePublic sector deployment of Oncoshot's AI platform for processing unstructured oncology data. Results highlighted in presentations at IACR 2025 alongside Tan Tock Seng Hospital.
- Omega Group of HospitalscorePartnership between Oncoshot India and Omega Hospitals to revolutionize cancer care in India. Omega Hospitals is a leading integrated healthcare delivery system founded in 2010 with advanced technologies including Ethos LINAC AI-powered radiation therapy, digital PET-MRI, CyberKnife VSI, and surgical robotics. Collaboration aims to expedite development of innovative cancer therapies and expand access to cutting-edge treatments.
- IIT Bombay (KCDH - Koita Centre for Digital Health)coreStrategic MOU between IIT Bombay and Oncoshot India for healthcare data exchange innovation, clinical trial efficiency, and AI/machine learning applications. KCDH at IITB is India's first centre focused on driving academic programs, research, and industry collaborations in digital health. Joint research initiatives planned in healthcare analytics, AI, and machine learning.
- CŌRE DiagnosticscoreStrategic partnership to revolutionize oncology clinical trials by leveraging Oncoshot's federated architecture for secure health data exchange. CŌRE Diagnostics provides precision oncology diagnostics including genomics, histopathology, and transplant immunology. Collaboration aims to accelerate patient enrollment and improve precision oncology clinical trial efficiency.
- Zhejiang Ablaze MedicinecoreStrategic partnership to jointly pioneer AI-led innovations to transform speed, efficiency, and accessibility of global drug development programs. Zhejiang Ablaze Medicine is a leading service provider of end-to-end clinical trial solutions in China with over 20 years of experience and over 200 global customers. Oncoshot enters the China healthcare market through this partnership.
- Jaslok Hospital & Research CentrecoreStrategic alliance pairing Oncoshot India's real-time health insights exchange platform with Jaslok's legacy of comprehensive cancer care. Jaslok is one of India's oldest and most esteemed super-speciality tertiary care hospitals in Mumbai with 350 beds, 75 ICU beds, and over 300 consultants. Partnership aims to enhance international clinical trial collaboration and patient access to innovative treatments.
- Taipei Medical UniversitycorePartnership facilitated through BE Accelerator Program to leverage TMU's academic and clinical expertise alongside Oncoshot's technological solutions. TMU operates 6 affiliated hospitals with 3,000 beds and 9,000+ faculty and staff. Collaboration aims to amplify inbound trial opportunities and establish global presence through real-time insights exchange.
- BuzzreachcoreCollaboration to accelerate clinical trials in Japan, the third-largest pharmaceutical market worldwide. Buzzreach specializes in clinical trial site recruitment, retention, and project management solutions. Partnership focuses on feasibility assessments, participant screening, and enrollment, with studies beginning Q1 2024. Buzzreach won the Excellence Award at Japan Healthcare Business Contest 2023.
- Gleneagles Global HospitalscorePartnership to bring cancer clinical trial patient matching to South India across GGH group of hospitals spanning Bengaluru, Chennai, Hyderabad, and Mumbai. GGH is part of IHH Berhad Healthcare Group, one of the world's largest healthcare providers. Clinical trials coordinated by Global Clinical Research Services (GCRS). Reference model for the rest of the Indian clinical trials landscape.
- Basavatarakam Indo-American Cancer Hospital (BIACH)coreFirst-of-its-kind partnership for cancer patient matching for clinical trials in India. BIACH is a premier dedicated cancer institute in Hyderabad with over 500 beds, inaugurated by former PM Atal Bihari Vajpayee in 2000. Run on a not-for-profit basis. MOU signed in May 2022 with strategic and operational level execution.
- Invest VictoriaminorInvest Victoria facilitated Oncoshot's establishment of Australian headquarters in Melbourne, providing support for the company's international growth and case study documentation.
- NovotechminorPartnership supported by Invest Victoria. Novotech is a CRO partner in the Australian market.
- OmicominorPartnership supported by Invest Victoria. Omico is an Australian oncology network partner.
- RochecorePrior collaboration (2022) with Icon Cancer Centre and Roche to digitise genomic data. Workflow has since been fully automated. Roche is part of Oncoshot's oncology network ecosystem of pharmaceutical partners.
- Kolhapur Cancer CentrecorePartnership to open cancer clinical trial access to rural India. KCC is a comprehensive cancer care centre serving South-West Maharashtra, treating nearly 30,000 patients with 80% receiving free treatment through CSCRF and government schemes. Collaboration addresses the significant gap in cancer care access for rural populations where mortality rates are double those of urban India.
Scale indicators8 records
Recent moves6 records
Expansion highlights7 records
Oncoshot competitors and assessment
Company assessmentDirect peers
- Antidote (Antidote Technologies): Antidote runs a well-known clinical trial matching platform (formerly known as TrialReach) connecting patients with trials via structured eligibility matching. Directly comparable to Oncoshot's patient-to-trial matching and Recommend Tx functionality, although Antidote focuses more on US/EU patient recruitment while Oncoshot focuses on oncology and APAC.
- Trial Library: Trial Library focuses specifically on oncology trial matching, providing patient-trial eligibility tools to community oncology practices and sponsors. Direct peer given the oncology-only specialisation overlap with Oncoshot.
- Clinerion: Clinerion operates a federated network of hospital data for patient recruitment, feasibility, and real-world data analytics. Closely comparable to Oncoshot's federated architecture and hospital network model, though Clinerion has broader therapeutic area coverage.
- Deep 6 AI: Deep 6 AI uses NLP and AI to extract patient characteristics from EHR data for clinical trial matching and cohort feasibility. Comparable to Oncoshot's Real-Time Insights, Well-Characterised Registry, and Feasibility Marketplace modules for hospitals and sponsors.
- Massive Bio: AI-driven oncology clinical trial matching platform serving patients, providers, and pharma sponsors. Closely comparable to Oncoshot in oncology-only positioning and use of AI for patient-to-trial eligibility matching, with overlap in pharma/CRO and hospital customer segments.
- Mendel (Mendel.ai): Mendel applies LLMs to clinical trial recruitment by structuring EHR data and matching patients to eligible trials. Highly comparable to Oncoshot's Recommend Tx and in-premise medical LLM, with overlapping LLM-based clinical data extraction approach.
Regional players
- Buzzreach: Japan-based clinical trial site recruitment and patient engagement platform; existing Oncoshot partner for Japan. A regional peer in clinical trial matching/recruitment operating primarily in the Japanese market, comparable in scope but distinct in geography.
Broad incumbents
- TriNetX: TriNetX operates a federated global health research network connecting hospitals and pharma for trial feasibility, cohort discovery, and real-world evidence. Directly comparable to Oncoshot's hospital-pharma federated model, with broader therapeutic scope and larger installed base.
- IQVIA: IQVIA is the largest global CRO with embedded clinical trial matching, feasibility analytics, and real-world data products through its EHR data network. Represents the scaled-incumbent competitor that Oncoshot must differentiate against, especially for pharma/CRO customers.
- Veeva Systems: Veeva provides the Vault CTMS, eTMF, and clinical trial operations suite used by most large pharma sponsors. An established incumbent whose trial-management ecosystem competes with Oncoshot's Insite Workflow and clinical trial informatics modules.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Oncoshot social profiles
Digital presenceOncoshot compliance and trust
Trust signalCompliance8 records
Oncoshot financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oncoshot leadership team
Management profileNumber of profiles
Profiles7 records
Oncoshot subsidiaries and ownership
Company hierarchySubsidiaries1 record
Oncoshot funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oncoshot M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oncoshot
What does Oncoshot do?
Oncoshot operates a federated AI-powered real-time health insights exchange platform that connects cancer patients, hospitals, and pharmaceutical/CRO companies to accelerate oncology clinical trial enrollment. The platform deploys in-premise medical LLMs within hospital AWS environments, enabling AI-driven patient-to-trial matching, automated extraction of structured data from unstructured clinical reports, real-time feasibility assessments, and trial workflow collaboration without patient data ever leaving hospital premises. Hospitals and industry partners subscribe to the platform for trial matching insights, feasibility management, and workflow automation, while patients use a free self-service matching tool.
Is Oncoshot a public or private company?
Oncoshot is a private company. It is classified as venture growth investor backed and is currently operating.
When was Oncoshot founded?
Oncoshot was founded in 2018. It employs 11 to 50 people.
Where is Oncoshot based?
Oncoshot is headquartered in Singapore, Singapore, in the Asia region.
How does Oncoshot make money?
Four revenue lines are on record. Platform Access for Industry Partners are the primary driver. The others are platform Services for Hospitals, patient Support Services and data-Driven Insights and Analytics.
Who are Oncoshot's main competitors?
Direct peers on record are Antidote (Antidote Technologies), Trial Library, Clinerion, Deep 6 AI, Massive Bio and Mendel (Mendel.ai). Buzzreach is listed as a regional player. Broad incumbents are TriNetX, IQVIA and Veeva Systems.
Does Oncoshot have an API?
No public API is recorded for Oncoshot.
What industry is Oncoshot in?
Oncoshot's product category is Oncology Clinical Trial Matching Software. Its primary akta.pro industry code is HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation), with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 54151 and its SIC code is 8000.